Wockhardt in news

Wockhardt announced today morning that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), United States of America (USA) is supporting a Phase 1 clinical trial of Wockhardt’s novel once-a-day, multidrug-resistant (MDR) Gram-negative targeted antibiotic WCK 6777.

The trial will be conducted at NIAID’s Phase I clinical trial units in the USA. NIAID will sponsor the investigational new drug application for the study.

The Food and Drug Administration (USA) has granted a qualified infectious disease product designation to WCK 6777, which signifies its ability to meet unmet medical need and facilitates faster approval process.

The stock opened 1% higher at Rs.291.50 and rose 3% to hit an intraday high at Rs,298. Its 52-week high and low stands at Rs.741.75 and Rs.287.05 respectively.